FCMV
Foresite Capital Management VI Portfolio holdings
AUM
$178M
This Quarter Return
-19.51%
1 Year Return
–
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$224M
AUM Growth
–
Cap. Flow
+$224M
Cap. Flow
% of AUM
100%
Top 10 Holdings %
Top 10 Hldgs %
92.41%
Holding
14
New
14
Increased
–
Reduced
–
Closed
–
Top Buys
| 1 |
CG Oncology
CGON
|
$63.7M |
| 2 |
ALMS
Alumis Inc. Common Stock
ALMS
|
$33M |
| 3 |
CNTA
Centessa Pharmaceuticals
CNTA
|
$21M |
| 4 |
RAPT Therapeutics
RAPT
|
$19.8M |
| 5 |
BCAX
Bicara Therapeutics Inc. Common Stock
BCAX
|
$16.5M |
Top Sells
No sells this quarter
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
CG Oncology
CGON
$2.07B
| $63.7M | 28.39% |
+2,221,474
| New | +$63.7M |
|
|
ALMS
2
Alumis Inc. Common Stock
ALMS
$484M
| $33M | 14.72% |
+4,202,670
| New | +$33M |
|
|
CNTA
3
Centessa Pharmaceuticals
CNTA
$2.29B
| $21M | 9.35% |
+1,253,379
| New | +$21M |
|
|
4
RAPT Therapeutics
RAPT
$198M
| $19.8M | 8.8% |
+12,500,000
| New | +$19.8M |
|
|
BCAX
5
Bicara Therapeutics Inc. Common Stock
BCAX
$641M
| $16.5M | 7.37% |
+950,000
| New | +$16.5M |
|
6
Edgewise Therapeutics
EWTX
$1.57B
| $15.6M | 6.96% |
+585,000
| New | +$15.6M |
|
7
Structure Therapeutics
GPCR
$1.15B
| $11.4M | 5.08% |
+420,000
| New | +$11.4M |
|
8
Akero Therapeutics
AKRO
$3.64B
| $10.2M | 4.52% |
+365,000
| New | +$10.2M |
|
9
Corvus Pharmaceuticals
CRVS
$425M
| $8.46M | 3.77% |
+1,581,233
| New | +$8.46M |
|
10
Cullinan Oncology
CGEM
$444M
| $7.73M | 3.44% |
+634,558
| New | +$7.73M |
|
11
Allogene Therapeutics
ALLO
$255M
| $7.34M | 3.27% |
+3,448,275
| New | +$7.34M |
|
12
Kymera Therapeutics
KYMR
$2.87B
| $5.89M | 2.62% |
+146,332
| New | +$5.89M |
|
13
CASI Pharmaceuticals
CASI
$35.9M
| $3.76M | 1.68% |
+1,329,383
| New | +$3.76M |
|
14
Viridian Therapeutics
VRDN
$1.53B
| $37.8K | 0.02% |
+1,974
| New | +$37.8K |
|